A Review on Messenger Ribonucleic Acid (Mrna) Based Vaccine: A New Era in Immunization

Rupendra Mahilane, Sandip Prasad Tiwari, Ayushmaan Roy*

Faculty of Pharmacy, Kalinga University, Naya Raipur, Chhattishgarh India (492101)

ABSTRACT

Vaccination has been one of the most effective public health interventions in human history, leading to the eradication or control of many infectious diseases. Traditional vaccine approaches, including live attenuated, inactivated, and subunit vaccines, though effective, often involve complex, time-consuming manufacturing processes and present challenges related to safety, scalability, and adaptability. The advent of messenger RNA (mRNA)-based vaccine technology represents a transformative innovation in the field of immunization, offering a platform that is not only faster to design and produce but also highly adaptable to emerging infectious threats.[1]

Keywords: Vaccination, messenger RNA (mRNA, immunization.

INTRODUCTION

1.1 Background and Importance of Vaccines

Vaccines have revolutionized public health since their inception more than two centuries ago. Historically, they have drastically reduced or eliminated diseases such as smallpox, polio, measles, and diphtheria, saving millions of lives worldwide. The principle of vaccination is based on training the immune system to recognize and combat pathogens, such as viruses or bacteria, without exposing the body to the disease itself. Traditional vaccines typically use either weakened (live attenuated) or killed (inactivated) forms of the pathogen, or specific proteins (subunit vaccines) derived from the pathogen, to provoke an immune response.

1.2 Challenges with Traditional Vaccine Approaches

While traditional vaccines have saved countless lives, they are not without limitations:

- **Time-Consuming Production**: Growing viruses or bacteria, purifying antigens, and conducting rigorous safety testing are processes that can take several years.
- **Safety Risks**: Live attenuated vaccines, though effective, carry a slight risk of reverting to a pathogenic form, especially in immunocompromised individuals.

- **Storage and Transportation**: Some vaccines require strict cold-chain logistics, complicating distribution, especially in low-resource settings.
- **Adaptability Issues**: For rapidly mutating viruses like influenza or emerging pathogens like novel coronaviruses, traditional vaccine development often struggles to keep pace with the evolving threat.[2]

.

2. Emergence of mRNA-Based Vaccines

The concept of using nucleic acids (DNA or RNA) as therapeutic agents has intrigued scientists for decades. mRNA, or messenger RNA, is a transient molecule that carries genetic information from DNA to the cellular machinery responsible for protein synthesis. Harnessing mRNA for vaccines offers a unique approach: instead of delivering an antigen directly, the vaccine delivers genetic instructions that enable the recipient's own cells to produce the antigen internally.

The basic idea is simple yet revolutionary:

- The mRNA sequence encodes a viral protein (e.g., the spike protein of SARS-CoV-2).
- When administered, the mRNA enters host cells.
- Host cells then use the mRNA to produce the viral protein.
- The immune system recognizes this protein as foreign and mounts an immune response.

This method circumvents many of the limitations of traditional vaccines and offers an elegant solution to the need for speed and adaptability in vaccine development.

3. Historical Development of mRNA Technology

The journey toward successful mRNA vaccines has been long and complex:

- **Early Discoveries (1990s)**: Scientists demonstrated that injected mRNA could induce protein production in animals, but early experiments were hindered by instability and rapid degradation of the mRNA molecules.
- **Stabilization Techniques**: Research in the early 2000s led to modifications of mRNA (such as the use of pseudo uridine) that enhanced stability and reduced unintended inflammatory responses.
- **Delivery Mechanisms**: The development of lipid nanoparticles (LNPs) was a critical breakthrough. These tiny fat-like particles protect mRNA from degradation and facilitate its entry into cells.
- **Pre-Pandemic Research**: Prior to COVID-19, companies like Moderna and BioNTech were already working on mRNA vaccines for diseases like Zika virus and cancer

immunotherapy. These efforts laid the foundation for the rapid development of COVID-19 vaccines.[3]

4. COVID-19: Catalyst for mRNA Vaccine Success

The COVID-19 pandemic accelerated the adoption of mRNA technology. Faced with a rapidly spreading and deadly virus, the world needed vaccines urgently. Traditional vaccine timelines (5–10 years) were impractical. mRNA vaccines provided a viable solution:

- **Speed**: Once the genetic sequence of SARS-CoV-2 was published (January 2020), scientists designed mRNA vaccine candidates within days.
- **Manufacturability**: Unlike traditional vaccines requiring virus cultivation, mRNA vaccines could be synthesized in laboratories using chemical processes.
- **Adaptability**: If viral mutations emerged, new mRNA sequences could be rapidly designed and manufactured.

Clinical trials of the Pfizer-BioNTech and Moderna vaccines showed exceptionally high efficacy (around 95%) and acceptable safety profiles, leading to emergency use authorizations within a year — an unprecedented achievement.

5. Advantages of mRNA Vaccines

mRNA vaccines offer several critical advantages over conventional vaccine technologies:

- **Rapid Development**: Once a pathogen's genetic sequence is known, mRNA vaccines can be designed in a matter of weeks.
- **Safety**: There is no risk of infection because no live virus is used.
- **Flexibility**: mRNA platforms can be easily adapted for new diseases or emerging variants.
- **Strong Immune Response**: Clinical studies showed mRNA vaccines could induce both robust antibody and T-cell responses.
- **Scalability**: mRNA vaccine production can be standardized and scaled up rapidly compared to traditional biological methods.[4]

6. Challenges and Limitations of mRNA Vaccines

Despite their advantages, mRNA vaccines are not without challenges:

- **Storage Requirements**: Early mRNA vaccines required ultra-cold storage (-70°C for Pfizer-BioNTech), making distribution difficult, particularly in low-resource settings.
- **Short-Term Data**: Long-term efficacy and potential for rare side effects are still being monitored.

- **Cost**: Initial manufacturing and distribution costs were high, although they are expected to decrease over time.
- **Public Acceptance**: As a novel technology, mRNA vaccines faced scepticism and misinformation, impacting public confidence.

Researchers are actively working to overcome these challenges, particularly by developing thermostable mRNA vaccines and improving public education on vaccine safety.

7. Future Applications of mRNA Technology

The success of mRNA vaccines during the COVID-19 pandemic has opened up a world of possibilities beyond infectious diseases:

- **Cancer Vaccines**: mRNA vaccines could be designed to target specific tumour antigens unique to an individual's cancer.
- **Personalized Medicine**: mRNA therapies could enable patient-specific treatments for a variety of conditions, including autoimmune diseases and genetic disorders.
- **Other Infectious Diseases**: Research is underway for mRNA vaccines against influenza, HIV, Zika virus, rabies, and cytomegalovirus (CMV).
- **Protein Replacement Therapies**: mRNA could be used to produce missing or deficient proteins in genetic diseases like cystic fibrosis.

The versatility of mRNA technology holds promise for transforming not just vaccination, but many fields of medicine.[5]

2.1 Elucidating the Scientific Principles Underlying mRNA Vaccine Design and Function

2.1.1 Detailed Analysis of mRNA Molecular Architecture

- **Background & Significance:**
  - Native mRNAs consist of a 5′ cap, 5′ untranslated region (UTR), coding sequence, 3′ UTR, and a poly(A) tail. Each element controls stability, translational efficiency, and innate immune recognition.
  - Understanding how synthetic constructs mimic or improve upon natural mRNA is fundamental to vaccine success.
- **Approach:**
  - **Literature Synthesis:** Comprehensive review of biochemical and structural biology studies detailing cap analogs (e.g., CleanCap, anti-reverse cap analogs), optimized UTR sequences from highly expressed genes (e.g., α- and β-globin UTRs), and tuning poly(A) tail lengths.

    - **Comparative Tables:** Tabulate key studies that vary one element at a time (e.g., cap vs. cap-1, short versus long poly(A) tails) and report effects on half-life and protein yield in vitro and in vivo.

- **Expected Outcomes:**
    - A hierarchical map linking specific mRNA design features to quantifiable metrics: half-life extension, innate immune evasion (e.g., reduced IFN-α/β induction), and translation rates (measured in pg protein/cell).

2.1.2 In-Depth Examination of Lipid Nanoparticle (LNP) Delivery Systems

- **Background & Significance:**
    - LNPs are the keystone of mRNA vaccine delivery, protecting cargo from ribonucleases, enabling endocytosis, and mediating endosomal escape.
- **Approach:**
    - **Component Breakdown:** Analyze the role of each LNP constituent:
        - **Ionizable lipids** (e.g., ALC-0315 in BNT162b2, SM-102 in mRNA-1273)
        - **Helper lipids** (DSPC, DOPE)
        - **Cholesterol** for membrane fluidity
        - **PEG-lipids** for steric stabilization and circulation half-life
    - **Physicochemical Characterization:** Compile data on particle size distributions, zeta potentials, and encapsulation efficiencies from key publications.
    - **Mechanistic Studies:** Review fluorescence/ electron-microscopy and pH-sensitive dye assays demonstrating LNP endosomal escape kinetics.
- **Expected Outcomes:**
    - A mechanistic model describing how variations in lipid composition shift biodistribution (e.g., liver vs. lymph node uptake), immunogenicity (inflammatory cytokine profiles), and optimal dosing regimens.

2.1.3 Mechanisms of Antigen Expression, Processing, and Presentation

- **Background & Significance:**
    - The nature of antigen presentation dictates the balance between humoral (B cell) and cellular (T cell) immunity, influencing vaccine efficacy.
- **Approach:**

- **Intracellular Trafficking:** Review endosomal escape to cytosolic release, ribosomal engagement, and post-translational modifications (glycosylation patterns on spike protein).
- **MHC Pathway Analysis:** Distinguish pathways leading to MHC-I presentation (endogenous) versus MHC-II (cross-presentation) using dendritic cell culture studies and knockout mouse models.
- **Kinetics & Dose Response:** Summarize time-course studies measuring antigen levels by flow cytometry and ELISA post-injection in animal models.

2.2 Critically Examining the Advantages and Challenges of mRNA Vaccine Development

2.2.1 Dissecting the Core Advantages

- **Rapid Design & Manufacturing:**
  - Chart typical timelines: genome sequencing → in silico antigen design → in vitro transcription → purification → LNP formulation; compare 6–12 months (traditional) vs. 6–8 weeks (mRNA).
- **Modularity & "Plug-and-Play" Capability:**
  - Case studies redesigning mRNA constructs within weeks to target emerging variants (e.g., Beta, Delta, Omicron).
- **Safety Profile:**
  - Aggregate data on absence of replication-competent virus, risk of insertional mutagenesis (theoretical), and overall reactogenicity profiles.
- **Immune Potency:**
  - Meta-analysis of immunogenicity endpoints: geometric mean titers (GMTs) of neutralizing antibodies, frequency of polyfunctional CD4+ and CD8+ T cells measured by ICS (intracellular cytokine staining).

2.2.2 Mapping the Principal Challenges

- **Thermostability & Cold-Chain Logistics:**
  - Detailed breakdown of stability studies at –80 °C, –20 °C, 4 °C, and room temperature; include degradation kinetics (e.g., % mRNA integrity loss per day).
- **Rare Adverse Events & Safety Monitoring:**
  - Collate surveillance data: incidence of myocarditis (~12.6 cases per million after second dose in males 12–29) and anaphylaxis (~4.7 cases per million doses). Discuss hypotheses on mechanisms (e.g., PEG hypersensitivity).
- **Manufacturing Scale-Up & Raw Material Constraints:**

- Examine global supply chains for critical reagents: nucleoside triphosphates, capping enzymes, ionizable lipids. Review capacity bottlenecks in mRNA synthesis (bioreactor runs) and LNP assembly (microfluidics).

- **Economic Barriers & Equity:**
  - Cost-analysis comparing projected per-dose manufacturing costs ($1–$2 in high-volume settings) versus selling prices ($19.50 for BNT162b2 initial contracts). Discuss tech-transfer initiatives (COVAX mRNA vaccine hub in South Africa).

MECHANISM OF ACTION

Mechanism of Action of mRNA Vaccines

The fundamental mechanism by which mRNA vaccines work reflects the elegance of leveraging the body's own machinery:

1. Uptake into Cells: Upon intramuscular injection, LNPs carrying mRNA are absorbed primarily by antigen-presenting cells (APCs), such as dendritic cells.

2. Protein Production: Inside the cytoplasm, the host's ribosomes read the mRNA sequence and synthesize the encoded antigenic protein—typically the viral spike protein in the case of SARS-CoV-2.

3. Antigen Presentation: The newly produced protein is either displayed on the cell surface through major histocompatibility complex (MHC) molecules or secreted for recognition by other immune cells.

4. Immune Activation:
   - B cells are stimulated to produce neutralizing antibodies targeting the antigen.
   - Helper T cells (CD4+) enhance the immune response by aiding B cells and activating cytotoxic T cells.
   - Cytotoxic T cells (CD8+) are primed to recognize and destroy infected cells presenting the antigen.

This coordinated immune response ensures not only immediate protection through antibodies but also longer-term memory via T and B memory cells, enabling rapid and robust responses upon future exposure to the pathogen.[7]

CONCLUSION

The development and deployment of mRNA vaccines during the COVID-19 pandemic represent a monumental achievement in medical science. This innovative platform offers solutions to many of the limitations associated with traditional vaccines and holds the potential to address a wide variety of future healthcare challenges. As researchers continue to refine and expand the applications of mRNA technology, we are witnessing the dawn of a new era in immunization — one characterized by speed, adaptability, personalization, and global accessibility. In the following chapters, we will explore the detailed scientific foundation, literature developments, clinical successes, and future prospects that define this exciting transformation in the field of immunology.

References

1. Karikó K, Buckstein M, Ni H, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. *Mol Ther*. 2005;16(11):1833–1840.
2. Thess A, Grund S, Fehlmann T, et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. *Mol Ther Nucleic Acids*. 2015;4:e297.
3. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. *Nat Rev Drug Discov*. 2018;17(4):261–279.
4. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. *Nat Rev Drug Discov*. 2014;13(10):759–780.
5. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. *Nat Rev Mater*. 2021;6(12):1078–1094.
6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med*. 2020;383(27):2603–2615.
7. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med*. 2021;384(5):403–416.